Enact Holdings, Inc.
NASDAQ:ACTInsurance - Specialty
+$0.07 today
- Market cap
- $6.05B
- Beta
- 0.48
- P/E (TTM)
- 8.9
- EPS (TTM)
- $4.78
- Dividend yield
- 2.04%
Volume 0.41M
Average 0.30M
ACT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Enact Holdings, Inc.NASDAQ: ACT
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development remains negative
Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How ACT compares with its peers on the latest reported figures
- ACT's LTM Jun 2026 research & development of $0 is the highest of the 7 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for ACT, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ACT) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for ACT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.12B | 1.09B | 1.15B | 1.2B | 1.23B |
| Cost of Revenue | 371.63M | 145.13M | 250.31M | 261.63M | 109.53M |
| Gross Profit | 748.56M | 949.75M | 903.38M | 940.31M | 1.12B |
| Gross Margin | 66.8% | 86.7% | 78.3% | 78.2% | 91.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 53.34M | 51.53M | 51.87M | 62.25M | 262.02M |
| Depreciation & Amortization | 3.33M | 5.2M | 0 | 0 | 0 |
| EBITDA | 749.55M | 955.12M | 903.38M | 929.22M | 908.79M |
| EBITDA Margin | 66.9% | 87.2% | 78.3% | 77.3% | 73.9% |
| Operating Income | 695.22M | 898.22M | 851.51M | 878.06M | 858.84M |
| Operating Margin | 62.1% | 82.0% | 73.8% | 73.1% | 69.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 51.01M | 51.7M | 51.87M | 51.16M | 49.95M |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | 695.22M | 898.22M | 851.51M | 878.06M | 858.84M |
| Pre-Tax Margin | 62.1% | 82.0% | 73.8% | 73.1% | 69.8% |
| Income Tax Expense | 148.53M | 194.07M | 186M | 189.99M | 184.59M |
| Net Income | 546.69M | 704.16M | 665.51M | 688.07M | 674.24M |
| Net Margin | 48.8% | 64.3% | 57.7% | 57.2% | 54.8% |
| EPS (Basic) | 3.36 | 4.32 | 4.14 | 4.40 | 4.54 |
| EPS (Diluted) | 3.36 | 4.31 | 4.11 | 4.37 | 4.52 |
| Weighted Avg Shares | 162.84M | 162.84M | 160.87M | 156.28M | 148.37M |
| Weighted Avg Shares (Diluted) | 162.88M | 163.29M | 161.85M | 157.55M | 149.32M |
Enact Holdings, Inc.
NASDAQ:ACT
Intrinsic Alpha fair value
Locked
Current Price
$45.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.